Thiago Carvalho on Nostr: 'Despite Flatiron struggling to make money, one benefit of the acquisition is that ...

'Despite Flatiron struggling to make money, one benefit of the acquisition is that its data has helped to improve cancer drug development at Roche, which is currently testing about 60 oncology drugs in clinical trials.'
https://www.ft.com/content/3f87d26c-c98d-42f4-b460-5011e255aa95